Relationship between platelet parameters and disease severity and coagulpathy in covid 19
Abstract
Objectives: Coagulopathy plays an important role in the clinical course of Covid-19 disease. The aim of our study is to examine the factors affecting the severity of this disease and to examine whether there is a relationship between platelet parameters and disease severity and coagulopathy markers.
Methods: The study was planned single-center, retrospective, and cross-sectional. 189 patients diagnosed with Covid-19 were admitted to the Internal Medicine Department. Patients were divided into 3 clinical categories according to the severity of the disease. The relationship between mean platelet volume and other platelet parameters, and disease severity and coagulopathy parameters were statistically analyzed.
Results: The study included 189 patients.182 of whom were discharged and 7 of whom died. The average age of the patients was 54.13 ± 14.21. D-Dimer levels were compared between the groups and were found to be significantly higher in cases of severe pneumonia. The group with severe pneumonia group had a higher PDW level than other groups. MPV was detected over 10 fl in the severe pneumonia group, but no statistically significant difference was found with the other groups. PT and INR levels are higher in patients with upper respiratory tract infection (URTI) compared to patients with mild to moderate pneumonia. APTT levels were found to be higher in patients with URTI than in patients with severe pneumonia.
Conclusion: In our study, PDW height and MPV height were determined from the findings showing platelet activation in patients with severe pneumonia. If an increase in these parameters is detected in patients diagnosed with the Covid 19 disease, close follow-up should be performed in terms of the development of complications.
Keywords
References
- Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9: 221.36.
- C. Calisher, D. Carroll, R. Colwell, R.B. Corley, P. Daszak, C. Drosten, L. Enjuanes, J. Farrar, H. Field, J. Golding. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19, The Lancet, 395 (2020) e42-e43.
- J. P. Metlay, G. W. Waterer, A. C. Long, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America, Am. J. Respir Crit Care Med 200(2019): e45–e67.
- Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2(ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46(4):586-590.
- Han H, Yang L, Liu R, at al. Prominent changes in blood coagulation of patient with SARS-Cov-2 infection. Clin Chem Lab Med 2020.
- Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
- Von Hundelshausen P, Weber C. Platelets as immune cells. Bridging inflammation and cardiovascular disaese. Circ Res 2007;100: 27-40.
- Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996 Mar;7(2):157- 161.
- Van der Lelie J, Von dem Borne AEG. Platelet volume analysis for differential diagnosis of thrombocytosis. J Clin Pathol 1986;39: 129.
- Tavil Y, Sen N, Yazici H, et al. Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients. Platelets 2010;21(5):368-372.